Clinical trials: First Line Treatment
Advanced or Metastatic Biliary Tract Cancer
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
The purpose of the study is to assess the efficacy of varlitinib in combination with capecitabine as measured by objective response rate (ORR) assessed by independent central review (ICR), based on RECIST v1.1 criteria.
- Trial name
- NCT03129074
- Testing
- Varlitinib, Capecitabine
- Sponsor
- ASLAN Pharmaceuticals
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Prostate Cancer, Hormone Refractory
Sutent Maintenance After Response to Taxotere
The major goal is to determine whether the experimental agent has clinically promising activity that would merit progression to a formal phase III trial.
- Trial name
- SMART (NCT00550810)
- Testing
- Sunitinib (SU011248)
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Alberta Health services
Non-small Cell Lung Cancer
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
This is a multicenter, single-arm phase II clinical study to evaluate the safety and efficacy of pyrotinib maleate as a first-line treatment for HER2-mutated or amplified non-small cell lung cancer.
- Trial name
- NCT05751018
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Adenocarcinoma
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT06789679
- Testing
- Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Non-Small Cell Lung Cancer
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether S-1 in combination with Cisplatin is effective as 1st line therapy in slowing tumor activity in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00651833
- Testing
- S-1
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Metastatic Renal Cell Carcinoma
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when…
- Trial name
- SUNRISES (NCT01784978)
- Testing
- Sunitinib, Everolimus
- Where
- 10 sites in France, Greece and 1 more
- Volunteers
- 41 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV
A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer
RATIONALE: Recently, the importance of prognosis according to the location of the primary tumor in colorectal cancer has been raised.
- Trial name
- NCT03641976
- Testing
- A-FOLFOXIRI, Arm II (A-FOLFOX/A-FOLFIRI)
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Yonsei University
Non-Small Cell Lung Cancer
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
- Trial name
- ATRACT-1 (NCT00662597)
- Testing
- ASA404, carboplatin, Paclitaxel
- Where
- 248 sites in United States, Argentina and 24 more
- Volunteers
- 1,285 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-squamous Non-small Cell Lung Cancer
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
This is Phase 3, randomized, open-label, parallel controlled study designed to compare the efficacy and safety of TQB2450 in combination with platinum-containing chemotherapy followed by TQB2450 plus Anlotinib versus tislelizumab…
- Trial name
- NCT05346952
- Testing
- TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biliary Tract Cancer (BTC), First-line Therapy
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Based on unmet clinical needs, relevant research backgrounds, and scientific evidence, it is planned to conduct a prospective, dual-cohort exploratory study.
- Trial name
- NCT07129018
- Testing
- Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC, Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC
- Volunteers
- 63 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Helicobacter Pylori Infection
PPI-amoxicillin for H. Pylori Treatment
This randomized controlled clinical trial will identify the additional benefit of bismuth or metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori first-line treatment.
- Trial name
- NCT05014685
- Testing
- Rabeprazole, Bismuth potassium citrate, Metronidazole
- Where
- China
- Volunteers
- 732 people
- Sponsor
- Shanghai Zhongshan Hospital
Older Adults (60 - 85 Years Old), OA Knee
Home-Based Quadriceps Isometric Exercise for Knee Osteoarthritis Pain
Knee osteoarthritis is a common cause of pain and reduced mobility in older adults. Many people have limited access to supervised rehabilitation programs, highlighting the need for simple and safe home-based treatment options.
- Trial name
- KOA-ISO01 (NCT07445568)
- Testing
- Cannabidiol (CBD) Topical Gel, Arnica montana Topical Gel, Home-based Quadriceps Isometric Exercise
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Universidad del Valle de México, Campus Cuernavaca
Esophageal Squamous Cell Carcinoma
Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
This phase Ⅱ study was designed to evaluate the efficacy and safety of endostar combined with paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or metastatic esophageal squamous cell cancer.
- Trial name
- NCT02350517
- Testing
- Paclitaxel+Nedaplatin+Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Yuhong Li
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.
- Trial name
- NCT00503568
- Testing
- Ad100-gp96Ig-HLA A1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Miami
Generalized Convulsive Status Epilepticus, Intensive Care Unit
Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.
Study Hypothesis Generalized Convulsive Status Epilepticus (GCSE) is a medical emergency associated with an increased morbidity and a prolonged length of hospital stay.
- Trial name
- VALSE (NCT01791868)
- Testing
- Intravenous Sodium Valproate
- Where
- France
- Volunteers
- 245 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CRC (Colorectal Cancer)
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
- Trial name
- NCT07284849
- Testing
- INCA33890, Bevacizumab, FOLFOX
- Where
- 297 sites in United States, Argentina and 20 more
- Volunteers
- 700 people
- Sponsor
- Incyte Corporation
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.